Background: There is limited evidence on the safety and efficacy of administering Ayurveda interventions as add-on to the standard care for COVID-19. Objective: To explore the therapeutic efficacy and safety of AYUSH-64 as an add-on to standard care in the management of mild to moderate stage COVID-19.Design, setting, participants and interventions: This was an open-label randomized controlled trial with 80 patients of mild to moderate stage COVID-19. Participants in the AYUSH-64 add-on group received two tablets (500 mg each) three times daily for 30 days along with conventional standard care (Paracetamol, Cetirizine, Vitamin C, and Azithromycin). The control group received standard care alone. Main outcome measures: The primary outcome assessed was the proportion of participants with clinical recovery and negative RT-PCR assay for COVID-19 on day 7, 15, 23, and 30. Additionally, change in pro-inflammatory markers, metabolic functions, HRCT chest and incidence of Adverse Drug Reaction (ADR) / Serious Adverse Event (SAE) were assessed.Results: Statistically significant difference was observed in the proportion of participants with clinical recovery in the AYUSH-64 add-on group (p<0.001) at each of the scheduled follow-up visits. All the participants in the AYUSH-64 add-on group clinically recovered by day 23 compared to 32.4 per cent in the control group. The mean duration for clinical recovery in AYUSH-64 add-on group (5.8 ± 2.67 days) was less as compared to control group (10.0 ± 4.06 days). The proportion of participants who turned RT-PCR negative for COVID-19 on day 7, 15, and 23 were 81.8, 94.5, and 100 per cent in AYUSH-64 add-on group, and 79.4, 94.5, and 97.2 per cent in control group, however, the difference observed was statistically not significant (p=0.314). The proportion of participants with improvement in HRCT chest was statistically significant in AYUSH-64 add-on group (p=0.031) unlike in control group (p=0.210). Similar reductions in most inflammatory markers measured (IL-6, CRP, Serum ferritin, and LDH) on day 30 (p<0.05) were observed in both groups. Conclusion: AYUSH-64 as adjunct to standard conventional care is safe and hastens clinical recovery in adult patients with mild to moderate COVID-19.

Background: The COVID-19 virus is a new pathogen that is highly contagious which has made a huge impact on health, economic and societal of our country. Prevention and control of COVID-19 infection focuses on early recognition, immediate isolation and implementation of appropriate infection prevention and control (IPC) measures. As of now symptomatic care is given to the patients. This particular retrospective study is done to analyze and understands the outcome of Ayurvedic Interventions in the management of mild symptomatic COVID-19 patients.Objective: To analyze the outcome of Ayurvedic interventions in managing mild symptomatic COVID-19 infected cases Materials and methods: Lab confirmed COVID-19 infected patients admitted at Shri Dhanwantry Ayurvedic College and hospital, Chandigarh was treated with Ayurvedic interventions. The data was collected and has been analyzed retrospectively. Data collected was being systematically analyzed and presented using appropriate software (SPSS version 21).Result: The interventions were administered in this particular study were aimed at dissipating the pathogenesis based on Ayurvedic principles of management. Increased clinical recovery rate was observed in major symptoms of COVID-19 i.e. Fever, cough and sore throat. Conclusion: The clinical recovery rate was observed in this study is 94.3% which is comparatively high in reference to current clinical recovery rate i.e. 69.5% in Chandigarh.Ethical Clearance Number: 8-55/2020-CARIRD/TECH/COVID/149 (Dated: 02/07/2020)